Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,600.00
-1,380.00 (-12.57%)
At close: Dec 5, 2025
18.23%
Market Cap 124.28B
Revenue (ttm) n/a
Net Income (ttm) -9.82B
Shares Out 12.95M
EPS (ttm) -759.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,082,228
Average Volume 2,005,477
Open 10,830.00
Previous Close 10,980.00
Day's Range 9,590.00 - 10,830.00
52-Week Range 4,630.00 - 12,000.00
Beta 0.22
RSI 64.81
Earnings Date Nov 14, 2025

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.